A Single-dose, Randomized, Open-label, Two-period Crossover, Phase I Study to Evaluate Relative Bioavailability and Food-Effect of HA121-28 Tablet B in Healthy Subjects
Latest Information Update: 15 Mar 2022
At a glance
- Drugs HA121 28 (Primary)
- Indications Biliary cancer; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 11 Mar 2022 Status changed from recruiting to completed.
- 08 Nov 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Jan 2022.
- 08 Nov 2021 Status changed from not yet recruiting to recruiting.